株式会社Lunit Japan

Lunit Japan Co., Ltd. is the Japanese subsidiary of Lunit Inc., a company driven by the mission of “Conquering Cancer Through AI.”

The Lunit Group is a global medical AI company advancing cancer screening, diagnosis, and treatment support through AI technologies across medical imaging, pathology, and biomarker applications. Building on technologies and clinical expertise developed globally, we work closely with healthcare providers, research institutions, and industry partners to advance the real-world clinical use of medical AI.

Lunit Japan aims to support the responsible implementation of medical AI in ways that are well suited to Japan’s healthcare environment. Through business development, partnership development, clinical and academic activities, and product implementation support, we contribute to the sustainable and responsible adoption of AI across Japan’s healthcare system.

We are currently building and expanding our business foundation in Japan, with a focus on establishing direct sales capabilities, strengthening collaboration with partners, introducing new products to the market, and enhancing support for local customers.

As a lean and highly capable team, we value transparent communication, efficient ways of working, and a high degree of autonomy and accountability. By combining a deep understanding of and respect for Japan’s healthcare environment and customers with close collaboration across our global teams, we aim to bring new value to cancer care in Japan.